A unified framework for weighted parametric group sequential design (WPGSD)

Group sequential design (GSD) is widely used in clinical trials in which correlated tests of multiple hypotheses are used. Multiple primary objectives resulting in tests with known correlations include evaluating 1) multiple experimental treatment arms, 2) multiple populations, 3) the combination of multiple arms and multiple populations, or 4) any asymptotically multivariate normal tests. In this paper, we focus on the first 3 of these and extend the framework of the weighted parametric multiple test procedure from fixed designs with a single analysis per objective [32] to a GSD setting where different objectives may be assessed at the same or different times, each in a group sequential fashion. Pragmatic methods for design and analysis of weighted parametric group sequential design (WPGSD) under closed testing procedures are proposed to maintain the strong control of family-wise Type I error rate (FWER) when correlations between tests are incorporated. This results in the ability to relax testing bounds compared to designs not fully adjusting for known correlations, increasing power or allowing decreased sample size. We illustrate the proposed methods using clinical trial examples and conduct a simulation study to evaluate the operating characteristics.

[1]  M. Huque.  Validity of the Hochberg procedure revisited for clinical trial applications , 2016, Statistics in medicine.

[2]  Charles W. Dunnett,et al.  A Step-Up Multiple Test Procedure , 1992 .

[4]  Frank Bretz,et al.  Graphical approaches for multiple comparison procedures using weighted Bonferroni, Simes, or parametric tests , 2011, Biometrical journal. Biometrische Zeitschrift.

[5]  Michael A. Proschan,et al.  Effects of assumption violations on type I error rate in group sequential monitoring , 1992 .

[6]  Michael Rosenblum,et al.  Multiple testing procedures for adaptive enrichment designs: combining group sequential and reallocation approaches. , 2016, Biostatistics.

[7]  Multiplicity for a group sequential trial with biomarker subpopulations. , 2020, Contemporary clinical trials.

[8]  Sung-Bae Kim,et al.  Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Abdulkadir Hussein,et al.  Statistical Monitoring of Clinical Trials , 2008, Technometrics.

[10]  A. Tamhane,et al.  Step-down multiple tests for comparing treatments with a control in unbalanced one-way layouts. , 1991, Statistics in medicine.

[11]  Qing Liu,et al.  On Adaptive Extensions of Group Sequential Trials for Clinical Investigations , 2008 .

[12]  J. Whitehead,et al.  A generalized Dunnett Test for Multi-arm Multi-stage Clinical Studies with Treatment Selection , 2012 .

[13]  Yiyong Fu.  Step-Down Parametric Procedures for Testing Correlated Endpoints in a Group-Sequential Trial , 2018 .

[14]  Man Jin.  A parametric multiple test procedure to adaptive group-sequential trials allowing for mid-term modifications. , 2020, Contemporary clinical trials.

[15]  A. Tamhane,et al.  Allocating recycled significance levels in group sequential procedures for multiple endpoints , 2015, Biometrical journal. Biometrische Zeitschrift.

[16]  E. Seneta,et al.  Simple Stepwise Tests of Hypotheses and Multiple Comparisons , 2005 .

[17]  D A Follmann,et al.  Monitoring pairwise comparisons in multi-armed clinical trials. , 1994, Biometrics.

[18]  Hung-Ming Wang,et al.  Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study , 2019, The Lancet.

[19]  Frank Bretz,et al.  Multiple Testing in Group Sequential Trials Using Graphical Approaches , 2013 .

[20]  Y. Shentu,et al.  Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial , 2016, The Lancet.

[21]  Lingyun Liu,et al.  Adaptive multiarm multistage clinical trials , 2020, Statistics in medicine.

[22]  Frank Bretz,et al.  A unified framework for weighted parametric multiple test procedures , 2017, Biometrical journal. Biometrische Zeitschrift.

[23]  K. K. Lan,et al.  Discrete sequential boundaries for clinical trials , 1983 .

[24]  C. Mehta,et al.  Design and monitoring of multi‐arm multi‐stage clinical trials , 2017, Biometrics.

[25]  D L Demets,et al.  Group sequential procedures: calendar versus information time. , 1989, Statistics in medicine.

[26]  J. S. D. Cani,et al.  Group sequential designs using a family of type I error probability spending functions. , 1990, Statistics in medicine.

[27]  T R Fleming,et al.  Designs for group sequential tests. , 1984, Controlled clinical trials.

[28]  D I Tang,et al.  Closed Testing Procedures for Group Sequential Clinical Trials with Multiple Endpoints , 1999, Biometrics.

[29]  KyungMann Kim.  Group Sequential Methods with Applications to Clinical Trials , 2001 .

[30]  Frank Bretz,et al.  A simple and flexible graphical approach for adaptive group-sequential clinical trials , 2016, Journal of biopharmaceutical statistics.

[31]  M. Huque,et al.  A flexible fixed-sequence testing method for hierarchically ordered correlated multiple endpoints in clinical trials , 2008 .